In last trading session, Palisade Bio Inc. (NASDAQ:PALI) saw 7.1 million shares changing hands with its beta currently measuring 1.78. Company’s recent per share price level of $3.97 trading at -$0.05 or -1.24% at ring of the bell on the day assigns it a market valuation of $332.17M. That closing price of PALI’s stock is at a discount of -2872.29% from its 52-week high price of $118.00 and is indicating a premium of 48.61% from its 52-week low price of $2.04. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.35 million shares which gives us an average trading volume of 1.10 million if we extend that period to 3-months.
For Palisade Bio Inc. (PALI), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.08 in the current quarter.
Palisade Bio Inc. (NASDAQ:PALI) trade information
Upright in the red during last session for losing -1.24%, in the last five days PALI remained trading in the green while hitting it’s week-highest on Tuesday, 11/22/22 when the stock touched $3.97 price level, adding 37.87% to its value on the day. Palisade Bio Inc.’s shares saw a change of -93.89% in year-to-date performance and have moved 40.78% in past 5-day. Palisade Bio Inc. (NASDAQ:PALI) showed a performance of -20.60% in past 30-days. Number of shares sold short was 0.18 million shares which calculate 0.05 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $25.00 to the stock, which implies a rise of 84.12% to its current value. Analysts have been projecting $25.00 as a low price target for the stock while placing it at a high target of $25.00. It follows that stock’s current price would drop -529.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of -529.72% for stock’s current value.
Palisade Bio Inc. (PALI) estimates and forecasts
Statistics highlight that Palisade Bio Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -84.28% of value to its shares in past 6 months, showing an annual growth rate of 88.22% while that of industry is 4.40. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -119.00% in the current quarter and calculating -162.50% decrease in the next quarter.
Palisade Bio Inc. is more likely to be releasing its next quarterly report between November 14 and November 18 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Palisade Bio Inc. (NASDAQ:PALI)’s Major holders
Insiders are in possession of 12.43% of company’s total shares while institution are holding 2.02 percent of that, with stock having share float percentage of 2.30%. Investors also watch the number of corporate investors in a company very closely, which is 2.02% institutions for Palisade Bio Inc. that are currently holding shares of the company. Sargent Investment Group, LLC is the top institutional holder at PALI for having 0.67 million shares of worth $66330.0. And as of Sep 29, 2022, it was holding 0.94% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 0.27 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 0.38% of outstanding shares, having a total worth of $0.11 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 0.2 million shares of worth $80156.0 or 0.28% of the total outstanding shares. The later fund manager was in possession of 69410.0 shares on Jun 29, 2022, making its stake of worth around $28326.0 in the company or a holder of 0.10% of company’s stock.